CSF Biomarkers in Olmsted County: Evidence of 2 Subclasses and Associations with Demographics
Authors
Affiliations
Objective: We studied interrelationships between CSF biomarkers and associations with ε4 genotype, demographic variables, vascular variables, and clinical diagnosis in Olmsted County, Minnesota.
Methods: We included 774 Mayo Clinic Study of Aging participants (693 cognitively unimpaired [CU]; 71 with mild cognitive impairment [MCI]). CSF β-amyloid 42 (Aβ42), total tau (t-tau), and hyperphosphorylated tau (p-tau) were analyzed using Aβ42 CSF, t-tau CSF, and p-tau (181P) CSF electrochemiluminescence immunoassays. Bivariate mixture models were used to evaluate latent classes. We used linear regression models to evaluate independent associations of ε4, demographic factors, cardiovascular risk, and diagnosis with CSF biomarker levels. Results were weighted back to the Olmsted County population.
Results: Interrelationships between CSF Aβ42 and p-tau/t-tau were consistent with 2 latent classes in the general population. In subgroup 1 (n = 547 [71%]), we found a strong positive correlation between Aβ42 and p-tau (ρ = 0.81), while the correlation was much smaller in group 2 (ρ = 0.26, n = 227 [29%]). Group 2 was associated with older age, ε4 genotype, a diagnosis of MCI, and elevated amyloid PET. Overall, ε4 genotype and MCI were associated with Aβ42, while age was associated with p-tau/t-tau. There were no associations with sex, education, or vascular risk.
Conclusion: We hypothesize the population without dementia can be subdivided into participants with and without biological Alzheimer disease (AD) based on the combination of CSF Aβ42 and p-tau/t-tau (represented also by the p-tau/t-tau/Aβ42 ratio). In those without biological AD, common factors such as CSF dynamics may cause a positive correlation between CSF Aβ42 and p-tau/t-tau, while AD leads to dissociation of these proteins.
Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome.
Corriveau-Lecavalier N, Botha H, Graff-Radford J, Switzer A, Przybelski S, Wiste H Brain Commun. 2024; 6(4):fcae183.
PMID: 39021510 PMC: 11251771. DOI: 10.1093/braincomms/fcae183.
A limbic-predominant amnestic neurodegenerative syndrome associated with TDP-43 pathology.
Corriveau-Lecavalier N, Botha H, Graff-Radford J, Switzer A, Przybelski S, Wiste H medRxiv. 2023; .
PMID: 38045300 PMC: 10690340. DOI: 10.1101/2023.11.19.23298314.
CSF phosphorylated tau as an indicator of subsequent tau accumulation.
Cogswell P, Wiste H, Mielke M, Schwarz C, Weigand S, Lowe V Neurobiol Aging. 2022; 117:189-200.
PMID: 35764037 PMC: 9361359. DOI: 10.1016/j.neurobiolaging.2022.02.015.
Li T, Yao Y, Jiang X, Dong Q, Yu X, Wang T Alzheimers Res Ther. 2022; 14(1):66.
PMID: 35550625 PMC: 9097146. DOI: 10.1186/s13195-022-01010-x.
Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease.
Ramanan V, Heckman M, Lesnick T, Przybelski S, Cahn E, Kosel M Acta Neuropathol. 2022; 143(5):571-583.
PMID: 35412102 PMC: 9109940. DOI: 10.1007/s00401-022-02419-2.